IP Library Granted Patent US 9,580,684
Granted Patent B2
US 9,580,684 · App. 13/223,372 · Granted Feb 28, 2017

Methods and compositions for the generation and maintenance of regulatory T cells

Inventors: Arlene Sharpe (Brookline, MA); Loise M. Francisco (Belmont, MA); Vijay Kuchroo (Newton Center, MA)
Assignees: President and Fellows of Harvard College; The Brigham and Women's Hospital, Inc.
C12N5/0636A61K2035/122C12N2501/15C12N2501/48C12N2501/51C12N2501/515
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,580,684
App. No.
13/223,372
Granted
Feb 28, 2017
Kind
B2
Abstract

Methods and compositions for generating and maintaining induced regulatory T cells (iTregs) are provided. Methods and compositions for treating an autoimmune disorder, organ transplant rejection, graft versus host disease or allergic or hypersensitivity and inflammation are also provided.

Claims (13)

1. A method of generating an induced regulatory T cell (iTreg) comprising the steps of:

a) isolating a CD4 + Foxp3 − naïve T cell;

b) contacting the isolated naïve T cell with PD-L1 and/or PD-L2; and

c) examining the T cell for Foxp3 expression and/or the ability to suppress effector T cell (Teff) activation, wherein Foxp3 expression and/or the ability to suppress Teff activation is indicative of an iTreg.

2. The method of claim 1 , wherein the PD-L is immobilized.

3. The method of claim 2 , wherein the PD-L is immobilized on a bead or a cell.

4. The method of claim 1 , wherein the step of differentiating is performed in the presence of anti-CD3 antibody or anti-CD28 antibody.

5. The method of claim 4 , wherein the anti-CD3 antibody or the anti-CD28 antibody are present on a bead.

6. The method of claim 1 , wherein the step of differentiating is performed in the presence of transforming growth factor-beta (TGF-β).

7. The method of claim 1 , wherein the iTreg expresses forkhead box p3 (Foxp3).

8. The method of claim 1 , wherein the iTreg suppresses effector T cell (Teff) activation.

9. The method of claim 8 , wherein the Teff is a CD4 + Teff.

10. The method of claim 1 , wherein the PD-L antagonizes the Akt signaling pathway.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 22, 2019
From: FRANCISCO, LOISE; SHARPE, ARLENE H.
To: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Reel/Frame 048671/0206 →
CONFIRMATORY LICENSE Recorded Jan 20, 2012
From: HARVARD UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 027567/0509 →
Continuity (3)
Continuation PCTUS2010026498 · Mar 8, 2010
Provisional Application 61157995 · Mar 6, 2009
Related Publication 20120076805A1 · Mar 29, 2012